Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › hematological malignancies

Hematological malignancies

Part of Hematologic Malignancies

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for hematological malignancies

15 trials tracked for hematological malignancies: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 109 citations.

15Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 11 Phase 1 1
  1. Phase 3 Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS Completed · 109 cited
  2. Phase 4 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV Completed
  3. Phase 3 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients Completed
  4. Phase 2 Rituximab for Prevention of Chronic GVHD Completed
  5. Phase 2 A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors Completed
  6. Phase 2 Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings Completed
Show 9 more trials
  1. Phase 2 Pasireotide in Prevention of GI Toxicity Completed
  2. Phase 2 Reduced Intensity Haploidentical Transplant for Hematological Malignancies Completed
  3. Phase 2 Trial Of Double Umbilical Cord Blood Transplantation Completed
  4. Phase 2 Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM Completed
  5. Phase 2 Compassionate Use Study of Tenalisib (RP6530) Completed
  6. Phase 2 A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies Completed
  7. Phase 2 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Completed
  8. Phase 2 A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Completed
  9. Phase 1 Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hematological malignancies: what the trials found

Clinical evidence for hematological malignancies includes the use of Ribavirin 1. Additionally, Ibandronate was evaluated regarding bone mineral density, which showed a percentage change from baseline at 6 and 12 months ranging from 0.06 to -4.85 3.

The use of NiCord® (omidubicel) in transplant settings demonstrated specific outcomes: 24 patients experienced Grade 2/3 Bacterial or Invasive Fungal Infections by 100 days compared to 38 in the control group; 60.5 versus 48 patients remained alive and out of hospital in the first 100 days; and 34 versus 22 patients achieved platelet engraftment by 42 days 2.

Recent results — preliminary, needs further review

  • Pembrolizumab/vibostolimab coformulation showed a Dose-Limiting Toxicity (DLT) rate between 0.0% and 8.0%, with adverse event (AE) rates ranging from 80.0% to 97.6% 4.
  • Cyclophosphamide was evaluated for the cumulative incidence of Grade III-IV GVHD, which was recorded at 0.5152 and 0.3111 5.

For the clinician treating this condition

  • NiCord® (omidubicel) is associated with improved outcomes in early post-transplantation metrics, including higher rates of platelet engraftment by day 42 and more days alive out of hospital within the first 100 days compared to standard protocols 2.
  • Ibandronate was assessed for its impact on bone mineral density over a 12-month period 3.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients
Drug Pipeline Sys. Review
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients Drug exposure varies wildly in patients receiving fludarabine for blood cancers
This review examines fludarabine cellular pharmacology, specifically transport and metabolism, in patients receiving the medication for hema…
Drug exposure varies up to 14.5-fold between patients receiving fludarabine, directly linking low levels to treatment failure and death.
Frontiers May 19, 2026
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers
Genetics & Precision Medicine Sys. Review
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers New cell therapy upgrade helps immune cells survive longer in tumors
A mini-review explores mitochondrial engineering strategies to boost CAR-T cell efficacy against solid and hematological malignancies, highl…
A new approach to engineering immune cells could solve a major problem: why they stop working inside solid tumors.
Frontiers May 9, 2026
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
Dermatology Sys. Review
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Frontiers Apr 30, 2026
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies
Oncology Sys. Review
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies Adapter-based CAR T cells face hurdles in treating solid tumors and blood cancers
This narrative review examines the potential of adapter-based CAR T cells across multiple cancer types, including solid tumors and hematolog…
A review highlights that making these cells is hard work and they struggle against solid tumors, limiting their current use.
Frontiers Apr 24, 2026
Systematic review of pharmacist-led interventions in hematological malignancies
Drug Pipeline Meta-analysis
Systematic review of pharmacist-led interventions in hematological malignancies Pharmacists Help Blood Cancer Patients Avoid Dangerous Drug Risks
This systematic review of 33 studies examined pharmacist-led interventions for patients with hematological malignancies.
Adding a pharmacist to your care team can make taking complex medicines safer.
Frontiers Apr 24, 2026

Research across Hematologic Malignancies

Related studies from across the Hematologic Malignancies family.

Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants
Genetics & Precision Medicine
Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants Hidden Blood Mutations Rewrite Cancer Risk Rules For Millions
This observational analysis of UK Biobank data examined TP53 variants to distinguish germline from somatic clonal expansions and assess asso…
Many scary cancer gene findings in blood tests are not inherited but acquired later in life, changing how doctors assess risk for millions.
medRxiv Apr 16, 2026

Questions about hematological malignancies

How do pharmacist-led interventions help patients with hematological malignancies?

Pharmacist-led interventions improve medication management, adherence, and toxicity control in hematological malignancies, though effects on survival and hospitalization are less clear.

Full answer →